Compartmentalization of cerebrospinal fluid inflammation across the spectrum of untreated HIV-1 infection, central nervous system injury and viral suppression
Open Access
- 13 May 2021
- journal article
- research article
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 16 (5) , e0250987
Abstract
Objective: To characterize the evolution of central nervous system (CNS) inflammation in HIV-1 infection applying a panel of cerebrospinal fluid (CSF) inflammatory biomarkers to grouped subjects representing a broad spectrum of systemic HIV-1 immune suppression, CNS injury and viral control.Methods: This is a cross-sectional analysis of archived CSF and blood samples, assessing concentrations of 10 functionally diverse soluble inflammatory biomarkers by immunoassays in 143 HIV-1-infected subjects divided into 8 groups: untreated primary HIV-1 infection (PHI); four untreated groups defined by their blood CD4+ T lymphocyte counts; untreated patients presenting with subacute HIV-associated dementia (HAD); antiretroviral-treated subjects with ≥1 years of plasma viral suppression; and untreated elite controllers. Twenty HIV-1-uninfected controls were included for comparison. Background biomarkers included blood CD4+ and CD8+ T lymphocytes, CSF and blood HIV-1 RNA, CSF white blood cell (WBC) count, CSF/blood albumin ratio, CSF neurofilament light chain (NfL), and CSF t-tau.Findings: HIV-1 infection was associated with a broad compartmentalized CSF inflammatory response that developed early in its course and changed with systemic disease progression, development of neurological injury, and viral suppression. CSF inflammation in untreated individuals without overt HAD exhibited at least two overall patterns of inflammation as blood CD4+ T lymphocytes decreased: one that peaked at 200–350 blood CD4+ T cells/μL and associated with lymphocytic CSF inflammation and HIV-1 RNA concentrations; and a second that steadily increased through the full range of CD4+ T cell decline and associated with macrophage responses and increasing CNS injury. Subacute HAD was distinguished by a third inflammatory profile with increased blood-brain barrier permeability and robust combined lymphocytic and macrophage CSF inflammation. Suppression of CSF and blood HIV-1 infections by antiretroviral treatment and elite viral control were associated with reduced CSF inflammation, though not fully to levels found in HIV-1 seronegative controls.Keywords
Funding Information
- National Institute of Neurological Disorders and Stroke (R01NS094067)
This publication has 93 references indexed in Scilit:
- Cerebrospinal fluid neopterin decay characteristics after initiation of antiretroviral therapyJournal of Neuroinflammation, 2013
- The HIV-1 Env Protein: A Coat of Many ColorsCurrent HIV/AIDS Reports, 2012
- The effect of HIV infection and HAART on inflammatory biomarkers in a population-based cohort of womenAIDS, 2011
- Central Nervous System Immune Activation Characterizes Primary Human Immunodeficiency Virus 1 Infection Even in Participants With Minimal Cerebrospinal Fluid Viral BurdenThe Journal of Infectious Diseases, 2011
- Plasma Levels of Soluble CD14 Independently Predict Mortality in HIV InfectionThe Journal of Infectious Diseases, 2011
- HIV-associated neurocognitive disorders before and during the era of combination antiretroviral therapy: differences in rates, nature, and predictorsJournal of NeuroVirology, 2010
- HIV‐1 Viral Escape in Cerebrospinal Fluid of Subjects on Suppressive Antiretroviral TreatmentThe Journal of Infectious Diseases, 2010
- Antiretroviral Therapy and Central Nervous System HIV Type 1 InfectionThe Journal of Infectious Diseases, 2008
- Persistent Intrathecal Immune Activation in HIV-1-Infected Individuals on Antiretroviral TherapyJAIDS Journal of Acquired Immune Deficiency Syndromes, 2008
- AIDS dementia complex and HIV‐1 brain infection: Clinical‐virological correlationsAnnals of Neurology, 1995